Neuroleptic malignant syndrome versus serotonin syndrome: The search for a diagnostic tool

Annals of Pharmacotherapy

Volumn 45, Issue 9, 2011, Pages

  Sokoro, Abdulrazaq A H ^a   Zivot, Joel ^b   Ariano, Robert E ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b EMORY CLINIC   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Dopamine metabolites; Malignant hyperthermia; Neuroleptic malignant syndrome; Serotonin syndrome; SSRIs

Indexed keywords

ADRENALIN; ALENDRONIC ACID; ATORVASTATIN; BUDESONIDE; CATECHOLAMINE; CELECOXIB; CONJUGATED ESTROGEN; DESIPRAMINE; DOPAMINE; DOPAMINE DERIVATIVE; FLUCONAZOLE; FUROSEMIDE; HALOPERIDOL; HYDROXYZINE; LEVOTHYROXINE; LOPERAMIDE; LORAZEPAM; METADRENALIN; MOMETASONE FUROATE; OMEPRAZOLE; PREDNISONE; QUETIAPINE; RISPERIDONE; SALBUTAMOL; SEROTONIN; SEROTONIN DERIVATIVE; SUMATRIPTAN; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CATECHOLAMINE URINE LEVEL; CONSCIOUSNESS LEVEL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DOPAMINE URINE LEVEL; EMERGENCY WARD; FATALITY; FEMALE; FEVER; HUMAN; MORNING DOSAGE; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; SEROTONIN SYNDROME; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; CATECHOLAMINES; DIAGNOSIS, DIFFERENTIAL; DIBENZOTHIAZEPINES; DOPAMINE; FEMALE; HALOPERIDOL; HUMANS; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; RISPERIDONE; SEROTONIN; SEROTONIN SYNDROME;

EID: 80052434010     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P787     Document Type: Article

References (38)

1. Caroff SN. Neuroleptic malignant syndrome. J Clin Psychiatry 1980;41: 79-83.
2. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6.
3. Gomez-Esteban JC, Barcena J, Forcadas M, et al. Neuroleptic malignant syndrome and serotonin syndrome in a female patient: a clinicopathologic case. Clin Neuropharmacol 2009;32:299-300. DOI 10.1097/WNF.0b013e3181a939b9
4. Kish SJ, Kleinert R, Minauf M, et al. Brain neurotransmitter changes in three patients who had a fatal hyperthermia syndrome. Am J Psychiatry 1990;147:1358-62.
5. Nisijima K, Ishiguro T. Cerebrospinal-fluid levels of monoamine metabolites and gamma-aminobutyric-acid in neuroleptic malignant syndrome. J Psychiatr Res 1995;29:233-44.
6. Ueda M, Hamamoto M, Nagayama H, Okubo S, Amemiya S, Katayama Y. Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry 2001;71:111-3.
7. Wait SD, Ponce FA, Killory BD, Wallace D, Rekate HL. Neuroleptic malignant syndrome from central nervous system insult: 4 cases and a novel treatment strategy. Clinical article. J Neurosurg Pediatr 2009;4: 217-21.
8. Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999;22:151-8
9. Boyer EW, Shannon M. The serotonin syndrome N Engl J Med 2005; 352:1112-20.
10. Cohen LJ. Risperidone. Pharmacotherapy 1994;14:253-65.
11. Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55(suppl):13-7.
12. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses.]. Ann Med Psychol (Paris) 1960;118:145-52.
13. Shalev A, Munitz H. The neuroleptic malignant syndrome agent and host interaction. Acta Psychiatr Scand 1986;73:337-47.
14. Moyes DG. Malignant hyperpyrexia caused by trimeprazine. Case report. Br J Anaesth 1973;45:1163-4.
15. Boles JM, Lecam B, Mialon P, Pennec Y, Garre M. [Malignant hyperthermia induced by neuroleptics. Rapid cure with dantrolene]. Nouv Presse Med 1982;11:674.
16. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988;24:25-9
17. Coons DJ, Hillman FJ, Marshall RW. Treatment of neuroleptic malignant syndrome with dantrolene sodium a case-report. Am J Psychiatry 1982;139:944-5.
18. Goulon M, Rohan-Chabot P, Elkharrat D, Gajdos P, Bismuth C, Conso F. Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. Neurology 1983;33:516-8.
19. Misiaszek JJ, Potter RL. Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 1985;26:62-3, 66.
20. Weinberg S, Twersky RS. Neuroleptic malignant syndrome. Anesth Analg 1983;62:848-50.
21. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477-92.
22. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
23. Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother 1998;32:33-38. DOI 10.1345/aph.17204
24. Adityanjee, Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999;2:129-44.
25. Rosenberg MR, Green M. Neuroleptic malignant syndrome Review of response to therapy. Arch Intern Med 1989;149:1927-31.
26. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2009; 361:1714.
27. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase A levels in the brain an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006;63:1209-16.
28. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998;103:273-9.
29. Weyler W, Salach JI. Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J Biol Chem 1985; 260:13199-207.
30. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169-80.
31. Feibel JH, Schiffer RB. Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome a case-report. Am J Psychiatry 1981; 138:1115-6
32. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions. J Psychiatr Pract 2003;9:376-84.
33. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions (part II). J Psychiatr Pract 2004;10:177-81.
34. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 2005;28:197-204.
35. Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk-factors for neuroleptic malignant syndrome a case-control study. Arch Gen Psychiatry 1989;46:914-8.
36. Horn E, Lach B, Lapierre Y, Hrdina P. Hypothalamic pathology in the neuroleptic malignant syndrome. Am J Psychiatry 1988;145:617-20.
37. Koponen H, Repo E, Lepola U. Long-term outcome after neuroleptic malignant syndrome. Acta Psychiatr Scand 1991;84:550-1.
38. Levenson JL, Fisher JG. Long-term outcome after neuroleptic malignant syndrome. J Clin Psychiatry 1988;49:154-6.